UniCycive Therapeutics Inc (UNCY)

[Whalatane]

Talent and experience don't come cheap

As an Independent Board Director at Unicycive Therapeutics, Inc. (NASDAQ: UNCY), Sandeep “Steve” Laumas, M.D. brings a highly specialized trifecta of skills—medical expertise, buy-side portfolio management, and investment banking pedigree—to guide the company through its current inflection point.

Unicycive is transitioning from a clinical-stage biotech into a commercial-stage pharmaceutical provider, specifically focusing on its lead program, Oxylanthanum Carbonate (OLC), for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.

Dr. Laumas helps UNCY clear these critical commercialization, financial, and strategic hurdles in several key ways:

1. Navigating the Post-Approval Commercial TransitionUnicycive has an upcoming FDA PDUFA target action date of June 29, 2026, for OLC.Structuring Commercial Rollouts: Dr. Laumas’s background as a Chief Business Officer at Instil Bio provides direct operational insight into how to properly scale infrastructure. He can advise management on setting up the company's "UniSource" reimbursement hub and target the estimated $1+ billion U.S. dialysis market.Evaluating Third-Party Risk: Unicycive's initial OLC application was delayed due to compliance deficiencies at a third-party manufacturing vendor. Dr. Laumas's experience managing high-stakes corporate partnerships helps the board carefully vet and hold manufacturing and supply chain vendors accountable moving forward

.2. Capital Markets Strategy and Cash Runway ManagementWhile Unicycive possesses a cash runway expected to last into 2027, launching a new drug is an incredibly capital-intensive endeavor.Wall Street and Equity Expertise: Having spent years as a Managing Director and healthcare analyst at prominent investment funds (North Sound Capital, Balyasny), Dr. Laumas understands exactly how institutional investors think. He helps position UNCY to capital markets to maximize its valuation ahead of potential fundraising rounds.Structuring Secondary Offerings: His foundational investment banking experience at Goldman Sachs ensures the board can structure future dilutive or non-dilutive financing (such as debt, royalty monetization, or secondary equity offerings) under the most favorable corporate terms possible.

3. Executing M&A and Strategic Licensing OutThe kidney disease therapeutic landscape is heavily consolidated by large pharmaceutical players.Identifying Strategic Partners: Dr. Laumas has extensive history executing complex mergers and cross-border transactions (such as the RDD Pharma/Innovate merger). If Unicycive chooses to co-promote OLC or license its secondary pipeline candidate, UNI-494 (for Acute Kidney Injury), Dr. Laumas is the ideal board-level advisor to negotiate global out-licensing deals or regional partnerships.M&A Defense and Acquisition Readiness: If OLC secures FDA approval and demonstrates early market adoption, Unicycive could become a primary target for a corporate takeover. Dr. Laumas’s M&A expertise helps the board evaluate buyout offers to ensure they maximize shareholder value.

4. Oversight of Risk and GovernanceBiotech boards face immense regulatory and compliance scrutiny as they approach market commercialization.
As an experienced public board member, Dr. Laumas protects the company from regulatory pitfalls. He serves as an independent voice checking corporate compliance, executive compensation, and financial reporting standards, giving institutional investors the confidence needed to hold or build large equity positions in UNCY.

If OLC doesnt get approved those RSU's are going to be worth a lot less

His pay day will be if OLC is approved ...and UNCY is acquired

JMO
Kiwi
PS
Note these RSU's
2. Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer.

This payment is solely in common stock
So huge upside for him if he can help get OLC approved , in clinics and maybe a deal ...within a year.
Huge upside for us also